References
- 1. World Health Organization: WHO infectious disease report: leading cause of death. Vol. 2004, 1999.
- 2. Rubin MA, Samore MH. Antimicrobial use and resistance. Curr Infect Dis Rep. 2002; 4:491-7.10.1007/s11908-002-0034-y
- 3. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003; 36:1433-7.10.1086/375081
- 4. World Health Organization: WHO global strategy for containment of antimicrobial resistance. WHO/CDS/ DRS/2001.2: WHO, Geneva, 2001.
- 5. Byarugaba DK. Antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents. 2004; 24:105-10.10.1016/j.ijantimicag.2004.02.015
- 6. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother. 2002; 46:2540-5.10.1128/AAC.46.8.2540-2545.2002
- 7. Niyogi SK, Dutta P, Mitra U. Trends in antimicrobial resistance of Shigella species isolated from children with acute diarrhea. Indian Pediatr. 2000; 37:339-41.
- 8. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis. 1999; 5:18-27.10.3201/eid0501.990103
- 9. Patel SJ, Larson EL, Kubin CJ, Saiman L. A review of antimicrobial control strategies in hospitalized and ambulatory pediatric populations. Pediatr Infect Disease J. 2007; 26: 531-7.10.1097/INF.0b013e3180593170
- 10. Capoor MR, Nair D, Deb M, Aggarwal P. Enteric fever perspective in India: emergence of high-level ciprofloxacin resistance and rising MIC to cephalosporins. J Med Microbiol. 2007; 56:1131-2.10.1099/jmm.0.47170-0
- 11. Patrick DM, Marra F, Hutchinson J, Monnet DL, Ng H, Bowie WR. Per capita antibiotic consumption: how does a North American jurisdiction compare with Europe? Clin Infect Dis. 2004; 39:11-7.10.1086/420825
- 12. Buetow SA, Sibbald B, Cantrill JA, Halliwell S. Appropriateness in health care: application to prescribing. Social Sci Med. 1997; 45:261-71.10.1016/S0277-9536(96)00342-5
- 13. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992; 45: 1045-51.10.1016/0895-4356(92)90144-C
- 14. Samsa GP, Hanlon JT, Schmader KE, Weinberger M, Clipp EC, Uttech KM, et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994; 47: 891-6.10.1016/0895-4356(94)90192-9
- 15. Sandiumenge A, Diaz E, Rodriguez A, Vidaur L, Canadell L, Olona M, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother. 2006; 57:1197-204.10.1093/jac/dkl097
- 16. Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003; 37:1643-8.10.1086/379709
- 17. Tunger O, Dinc G, Ozbakkaloglu B, Atman UC, Algun U. Evaluation of rational antibiotic use. Int J Antimicrob Agent. 2000; 15:131-5.10.1016/S0924-8579(00)00158-8
- 18. LeMire M, Wing L, Gordon DL. An audit of third generation cephalosporin prescribing in a tertiary care hospital. Aust N Z J Med. 1996; 26: 386-90.10.1111/j.1445-5994.1996.tb01927.x8811213
- 19. Pickering TD, Gurwitz JH, Zaleznik D, Noonan JP, Avorn J. The appropriateness of oral fluoroquinoloneprescribing in the long-term care setting. J Am Geriatr Soc. 1994; 42: 28-32.10.1111/j.1532-5415.1994.tb06069.x8277111
- 20. Pinto Pereira L, Phillips M, Ramlal H, Teemul K, Prabhakar P. Third generation cephalosporin use in a tertiary hospital in Port of Spain, Trinidad: need for an antibiotic policy. BMC Infect Dis. 2004; 4:59.10.1186/1471-2334-4-5954506415601475